Vesnarinone (INN) is a cardiotonic agent.[1] A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.

Vesnarinone
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25N3O4
Molar mass395.459 g·mol−1
3D model (JSmol)
  • COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
  • InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26) ☒N
  • Key:ZVNYJIZDIRKMBF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Cavusoglu E, Frishman WH, Klapholz M (June 1995). "Vesnarinone: a new inotropic agent for treating congestive heart failure". Journal of Cardiac Failure. 1 (3): 249–257. doi:10.1016/1071-9164(95)90030-6. PMID 9420657.
edit